Financial writer bullish on the Health Care Select Sector SPDR ETF (XLV) for its valuation, technical setup, and diversified ...
Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.
Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...
FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...
Keytruda cuts risk of death by 20% in certain patients with gastric or gastroesophageal junction as a first-line combination ...
Merck (NYSE: MRK) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
Merck (MRK) closed at $115.86 in the latest trading session, marking a +0.53% move from the prior day. The stock fell short of the S&P 500, which registered a gain of 0.54% for the day. Meanwhile, the ...
One year after reporting a split result on Merck’s Welireg in a key phase 3 trial, the song remains the same for the kidney ...
Morning! Today, we’ll keep riding the bispecific wave, and tell you what Verily and FDA alum Amy Abernethy is up to next. Oh, and a programming note: The annual ESMO meeting opens this weekend ...
Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories. Rahway, New Jersey-based Merck just flashed a Death Cross, signaling ...
It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...